SONOMA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1899 USD | +0.05% |
|
-1.09% | +5.27% |
Valuation
| Fiscal Period: Marzo | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 4.539 | 2.596 | 3.565 | - |
| Enterprise Value (EV) 1 | 4.539 | 2.596 | 3.565 | 3.565 |
| P/E ratio | -0.64 x | -0.31 x | -0.95 x | -2.11 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 0.2 x | 0.21 x | 0.17 x |
| EV / Revenue | - | 0.2 x | 0.21 x | 0.17 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 4,649 | 15,607 | 18,774 | - |
| Reference price 2 | 0.9763 | 0.1663 | 0.1899 | 0.1899 |
| Announcement Date | 21/06/23 | 17/06/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 12.74 | 16.98 | 21.3 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -4.701 | -3.83 | -1.82 |
| Operating Margin | - | -36.91% | -22.56% | -8.54% |
| Earnings before Tax (EBT) 1 | - | -5.031 | -3.99 | -1.98 |
| Net income 1 | -5.151 | -4.835 | -3.99 | -1.98 |
| Net margin | - | -37.97% | -23.5% | -9.3% |
| EPS 2 | -1.520 | -0.5300 | -0.2000 | -0.0900 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 21/06/23 | 17/06/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 2.731 | 3.138 | 3.439 | 3.94 | 3.98 | 4.39 | 4.66 | 5.03 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -1.208 | -0.844 | -1.409 | -1.15 | -0.95 | -0.8 | -0.93 | -0.68 |
| Operating Margin | - | -44.23% | -26.9% | -40.97% | -29.19% | -23.87% | -18.22% | -19.96% | -13.52% |
| Earnings before Tax (EBT) 1 | - | -1.298 | -0.923 | -1.359 | -1.19 | -0.99 | -0.84 | -0.97 | -0.72 |
| Net income 1 | -1.418 | -1.484 | -0.866 | -1.067 | -1.19 | -0.99 | -0.84 | -0.97 | -0.72 |
| Net margin | - | -54.34% | -27.6% | -31.03% | -30.2% | -24.87% | -19.13% | -20.82% | -14.31% |
| EPS 2 | -0.2900 | -0.2900 | -0.0800 | - | -0.0600 | -0.0500 | -0.0400 | -0.0500 | -0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/08/23 | 13/11/23 | 08/02/24 | 17/06/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 21/06/23 | 17/06/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1899
USD
Average target price
1.5
USD
Spread / Average Target
+689.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.27% | 3.57M | |
| +55.19% | 815B | |
| +45.11% | 654B | |
| -6.09% | 354B | |
| +21.92% | 337B | |
| +18.83% | 247B | |
| +3.19% | 229B | |
| +13.75% | 219B | |
| +10.86% | 171B | |
| -2.78% | 159B |
- Stock Market
- Equities
- SNOA Stock
- Financials Sonoma Pharmaceuticals, Inc.
